Literature DB >> 29045693

Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia.

Sara N Salerno1, Janice Bernhardt2, Matthew Laughon2, Ravi Jhaveri2, Matthew Massaro2, Daniel Gonzalez1.   

Abstract

We report here the first pharmacokinetic-pharmacodynamic relationship for ceftaroline in a preterm infant born at <28 weeks' gestational age who was given ceftaroline (8.5 mg/kg every 8 hours) for pneumonia attributable to methicillin-resistant Staphyloccocus aureus. This dose of ceftaroline was adequate to achieve the pharmacodynamic endpoint associated with efficacy for methicillin-resistant Staphyloccocus aureus.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29045693      PMCID： PMC6276030          DOI： 10.1093/jpids/pix084

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  3 in total

1.  Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

Authors:  Stéphanie Leroux; Mark A Turner; Chantal Barin-Le Guellec; Helen Hill; Johannes N van den Anker; Gregory L Kearns; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

2.  Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.

Authors:  Todd A Riccobene; Tatiana Khariton; William Knebel; Shampa Das; James Li; Alena Jandourek; Timothy J Carrothers; John S Bradley
Journal:  J Clin Pharmacol       Date:  2016-09-27       Impact factor: 3.126
  3 in total
  1 in total

1.  Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future.

Authors:  Lucie Matrat; Frank Plaisant; Christine Barreto; Olivier Claris; Marine Butin
Journal:  Antimicrob Resist Infect Control       Date:  2020-09-23       Impact factor: 4.887
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.